Long COVID Research & Potential Treatments Part 1 (E27) Ft. Prof David Putrino скачать в хорошем качестве

Long COVID Research & Potential Treatments Part 1 (E27) Ft. Prof David Putrino

Dr. David Putrino highlights the complexity of Long COVID, emphasizing hormonal and neurological impacts. Research shows hormonal disruptions, including low cortisol, are common in some patients, influencing symptoms like fatigue. Gender-specific patterns reveal women often have low testosterone, while men show reduced estradiol, correlating with differing symptoms. Neurologically, Long COVID causes neuroinflammation and vagus nerve dysfunction, contributing to issues like cognitive impairment and POTS. Emerging treatments include medications, innovative devices like vagus nerve stimulators and magnetic resonance therapy, and procedures such as stellate ganglion blocks. These interventions, supported by ongoing research, offer hope for tailored therapies to address Long COVID’s diverse effects. Professor David Putrino is a physiotherapist with a PhD in Neuroscience. He is currently the Director of Rehabilitation Innovation for the Mount Sinai Health System, and a Professor in the Department of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai. Professor Putrino recently opened the Mount Sinai Cohen Center for Recovery from Complex Chronic Illness in New York also known as (CoRE) and serves as CoRE’s Family Director and is also a member of PolyBio’s Long COVID Research Consortium. Today we talk about the pathophysiology of Long COVID in the context of describing research into targeted treatments for the disease. Find out more at longcovidtheanswers.com This podcast is CERTIFED CONTINUED PROFESSIONAL DEVELOPMENT CPD/CME. Healthcare Professionals and can earn 0.5 MainPro+ Credits! Please register at https://longcovidtheanswers.com/cpd-r... and watch via the CPD/ CME dashboard area to claim your credits. REFERENCES 1 Proal AD, VanElzakkerMB, Aleman S, Bach K, Boribong BP, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19(PASC). Nature Immunology. 2023 Oct;24(10):1616-27. 2 Klein J, Wood J,Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA, Silva Monteiro V. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023 Nov 2;623(7985):139-48. 3 Long COVID low-dose Rapamycin clinical trial 4 Lumbrokinase LongCOVID & ME/CFS clinical trial 5 Silva J, Takahashi T, Wood J, Lu P, Tabachnikova A, Gehlhausen JR, Greene K, Bhattacharjee B, Monteiro VS, Lucas C, Dhodapkar RM. Sex differences in symptomatology and immune profiles of Long COVID. medRxiv. 2024 Mar 2:2024-02. 6 VanElzakker MB, Bues HF, Brusaferri L, Kim M, Saadi D, Ratai EM, Dougherty DD, Loggia ML. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C] PBR28 PET correlates with vascular disease measures. Brain, Behavior, and Immunity. 7 Fernández-CastañedaA, Lu P, Geraghty AC, Song E, Lee MH, Wood J, O’Dea MR, Dutton S, Shamardani K, Nwangwu K, Mancusi R. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022 Jul 7;185(14):2452-68. Copyright: Kojala Medical 2025 #longhauler #longcovid #monoclonalantibodies #longcovid